Saturday 17 October 2026 Export MIST’s income statement to Excel — free account

Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, up 54.6% from fiscal 2023. In the quarter to June 2026, revenue fell 62.7%, EPS fell 5.00%, free cash flow fell 80.8% and total debt rose 7.19%, each against the same quarter a year earlier.

0.71 0.09 −11.25%

Follow MIST

Alert me

Market cap: $98.9M
P/E: 0.0×
Fwd P/E: −1.3×
Dividend yield: —
F-score: n/a
Altman Z: −4.65
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 1.18

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	5	1	—	—	1	—	—	—	—	—	—

Insider Ownership 11.96%

Capital & Financial Ratios $m

Market Cap 98.91

Revenue 5.30

Net Income (84.01)

Free Cash Flow (61.65)

Net Debt (111.40)

Current Ratio 8.13

Debt/Equity 3.25

P/E ratio 0.00

Fwd P/E (1.32)

P/S ratio 18.59

P/B ratio 5.41

Past 5Y EPS Growth —

This Y EPS Growth (12.57%)

Next Y EPS Growth 1.02%

Next Y revenue growth 147.61%

Next 5Y EPS Growth 25.35%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 84.61%

10-year low 10-year high

P/B against its own 10 years 86.07%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	66	70	106	171
Receivables	3	1	3	3
Inventory	—	—	1	5
Other	1	1	0	1
	73	74	112	180

	2023	2024	2025	Q'26
Payables	7	8	13	8
ST’ Debt	—	—	—	—
Other	—	—	0	0
	7	8	14	22

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(53.11%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(21.83%)	(14.29%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	1	—	—	—
’25	—	—	—	—	2
’23	1	—	—	—	1
’22	—	—	2	4	5

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(23)	—	—	—
’25	(14)	(13)	(10)	(13)	(49)
’24	(9)	(6)	(7)	(7)	(29)
’23	(14)	(11)	(12)	(10)	(46)
’22	(14)	(14)	(12)	(13)	(52)
’21	(12)	1	(9)	(12)	(33)
’20	(18)	(17)	(7)	(9)	(51)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	(23)	—	—	—
’25	(14)	(13)	(10)	(13)	(49)
’24	(9)	(6)	(7)	(7)	(29)
’23	(14)	(11)	(12)	(10)	(47)
’22	(14)	(14)	(12)	(13)	(53)
’21	(12)	1	(9)	(12)	(33)
’20	(18)	(17)	(7)	(9)	(51)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.20)	(0.21)	—	—	—
’25	(0.31)	(0.20)	(0.12)	(0.16)	(0.75)
’24	(0.21)	(0.14)	(0.14)	(0.19)	(0.67)
’23	(0.35)	(0.37)	(0.35)	(0.32)	(1.39)
’22	(0.33)	(0.39)	(0.34)	(0.31)	(1.38)
’21	(0.30)	0.02	(0.34)	(0.40)	(1.02)
’20	(0.67)	(0.53)	(0.40)	(0.23)	(1.70)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	12.36	1.69	5.09	3.39	1.62	1.12	0.63	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	27.95	23.25	9.03	9.85	4.49	2.75	3.06
People
People	Employees	—	—	23	30	28	29	39	47	33	38
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.52	0.13	0.02	0.00	0.04
Income, $m
Income, $m	Revenue	—	—	—	—	—	15	5	1	—	2
	Gross margin, %	—	0.00	0.00	0.00	0.00	100.00	100.00	100.00	—	100.00
	EBT	—	(8)	(23)	(55)	(50)	(43)	(58)	(60)	(42)	(63)
	EBT margin, %	—	0.00	0.00	0.00	0.00	(285.69)	(1,167.76)	(5,968.50)	0.00	(4,078.78)
	Net income	—	(8)	(23)	(55)	(50)	(43)	(58)	(60)	(42)	(63)
	Depreciation	—	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.36	0.12	0.02	0.00	0.02
	Earnings	—	(34.15)	(72.63)	(3.50)	(1.70)	(1.02)	(1.38)	(1.39)	(0.67)	(0.75)
	Cash flow	—	(34.00)	(65.93)	(3.24)	(1.73)	(0.79)	(1.24)	(1.08)	(0.46)	(0.58)
	Capex	—	(0.15)	(0.02)	(0.03)	0.00	0.00	(0.01)	0.00	0.00	0.00
	Free cash flow	—	(34.16)	(65.95)	(3.27)	(1.73)	(0.79)	(1.24)	(1.08)	(0.46)	(0.59)
	Book value	—	(139.86)	(172.96)	7.28	4.88	2.69	1.56	0.39	0.21	0.50
	Shares, m	—	0	0	16	29	42	42	43	62	84
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	—	0.00
	P/S	—	—	—	—	—	0.00	0.00	3.68	—	8.07
	P/B	—	—	—	—	—	2.43	2.59	4.61	—	4.06
	EV/Sales	—	—	—	—	—	0.00	0.00	2.91	—	5.75
	EV/FCF	—	—	—	—	—	(4.77)	(2.07)	(1.31)	—	(2.45)
Cash, $m
Cash, $m	Operating cash flow	—	(8)	(21)	(51)	(51)	(33)	(52)	(46)	(29)	(49)
	Capex	—	0	0	0	—	—	0	0	0	0
	Free cash flow	—	(8)	(21)	(52)	(51)	(33)	(53)	(47)	(29)	(49)
Balance, $m
Balance, $m	Working capital	—	26	84	114	143	112	66	66	66	98
	Total debt	—	—	—	0	1	0	2	50	53	57
	Net debt	—	(27)	(86)	(120)	(142)	(114)	(63)	(16)	(16)	(49)
	Shareholders’ equity	—	(33)	(55)	115	143	113	66	17	13	42
Returns, %
Returns, %	ROA	—	(13.98)	(40.09)	(52.22)	(36.55)	(31.76)	(60.09)	(79.73)	(55.09)	(66.71)
	ROIC	—	0.00	0.00	0.00	(2,105.90)	0.00	(991.65)	(7,071.53)	0.00	0.00
	ROE	—	18.31	52.50	(185.00)	(38.73)	(33.52)	(65.26)	(143.61)	(277.55)	(229.65)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
UNCY Unicycive Therapeutics, Inc.	$100.0M	— (loss-making)	— (loss-making)	—	n/m	+9.77% (above 0%: growing)	0.00%	0.00%	Compare
BDTX Black Diamond Therapeutics, Inc.	$100.0M	— (loss-making)	— (loss-making)	—	n/m	+12.91% (above 0%: growing)	100.00%	0.00%	Compare
PYPD PolyPid Ltd.	$99.5M	— (loss-making)	—	—	n/m	−64.96% (below 0%: shrinking)	0.00%	0.00%	Compare
MIST Milestone Pharmaceuticals Inc.	$98.9M	— (loss-making)	— (loss-making)	−62.73% (below 0%: shrinking)	n/m	−80.81% (below 0%: shrinking)	94.28%	(4,584.97%)
CBUS Cibus, Inc.	$98.6M	— (loss-making)	— (loss-making)	+6.54% (above 0%: growing)	n/m	+31.62% (above 0%: growing)	100.00%	(1,300.30%)	Compare
PMVP PMV Pharmaceuticals, Inc.	$97.4M	— (loss-making)	—	—	n/m	+20.27% (above 0%: growing)	0.00%	0.00%	Compare
NRXS Neuraxis, Inc.	$97.2M	— (loss-making)	— (loss-making)	+115.71% (above 0%: growing)	n/m	+29.76% (above 0%: growing)	85.87%	(110.16%)	Compare
IMUX Immunic, Inc.	$96.9M	— (loss-making)	—	—	n/m	−26.79% (below 0%: shrinking)	0.00%	0.00%	Compare
ATRA Atara Biotherapeutics, Inc.	$96.9M	— (loss-making)	— (loss-making)	−96.42% (below 0%: shrinking)	n/m	+52.10% (above 0%: growing)	69.68%	(749.21%)	Compare
Median of peers	$98.0M	—	—	+6.54%	—	+16.59%	34.84%	0.00%

All 614 Biotechnology stocks →

Milestone Pharmaceuticals Inc. (MIST) key facts

Concern: Milestone Pharmaceuticals Inc. reported a net loss of $63.1 million, or a loss of $0.75 per share, for fiscal 2025.
Strength: Milestone Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, up 54.6% from fiscal 2023.
Milestone Pharmaceuticals Inc. (MIST) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MIST traded at $0.71, a market capitalization of $98.9 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 18.6× sales.
Return on equity was −229.7% and debt-to-equity 3.25.
Its Altman Z-score is −4.65 (distress zone) for fiscal 2025.